초록 ▼

A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be

A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

대표청구항 ▼

What is claimed is: 1. A composition comprising an excipient and a sulfoalkyl ether cyclodextrin composition, wherein the sulfoalkyl ether cyclodextrin composition comprises: (a) sulfoalkyl ether cyclodextrin; (b) no more than about 20% by weight moisture; (c) a bulk density of about 0.38 g/cm3 to

What is claimed is: 1. A composition comprising an excipient and a sulfoalkyl ether cyclodextrin composition, wherein the sulfoalkyl ether cyclodextrin composition comprises: (a) sulfoalkyl ether cyclodextrin; (b) no more than about 20% by weight moisture; (c) a bulk density of about 0.38 g/cm3 to about 0.66 g/cm3; (d) a tapped density of about 0.49 g/cm3 to about 0.75 g/cm3, wherein the tapped density of the sulfoalkyl ether cyclodextrin composition is higher than the bulk density; and (e) a gravitational-flow minimum orifice diameter of about 3 mm to about 12 mm; and wherein the sulfoalkyl ether cyclodextrin composition comprises agglomerated particles, wherein the agglomerated particles are produced by a process comprising: (i) forming a fluidized bed of SAE-CD particles in a drying chamber of a fluidized bed spray dryer apparatus with an attached 3-chamber fluidization bed; (ii) recycling fine particles from the fluidized bed back into the drying chamber at a location adjacent to a liquid feed atomizer; and (iii) collecting agglomerated particles from the third chamber of the 3-chamber fluidization bed. 2. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin is a compound, or a mixture of compounds, of the Formula 1: wherein: n is 4, 5, or 6; R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each, independently, O- or a O--(C2-6 alkylene)--SO3-group, wherein at least one of R1 and R2 is, independently, the O--(C2-C6 alkylene)--SO3-group; and S1, S2, S3, S4, S5, S6, S7, S8, and S9, are each, independently, a pharmaceutically acceptable cation. 3. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a bulk density of about 0.55 g/cm3 to about 0.66 g/cm3 and a tapped density of about 0.66 g/cm3 to about 0.75 g/cm3. 4. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a bulk density of about 0.38 g/cm3 to about 0.55 g/cm3 and a tapped density of about 0.49 g/cm3 to about 0.66 g/cm3. 5. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a gravitational-flow minimum orifice diameter of about 10 mm or less. 6. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a true density of about 1.1 g/cm3 to about 1.5 g/cm3. 7. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a CARR's index of about 12% to about 24%. 8. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises particles with a mean particle diameter of about 75 microns to about 200 microns. 9. The composition of claim 8, wherein at least 90% of the particle volume of the sulfoalkyl ether cyclodextrin composition comprises particles having calculated diameters greater than or equal to about 25 microns. 10. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a moisture content of about 2% to about 3% by weight and a compression crushing strength of about 1.0 kP to about 20 kP when compressed into a tablet using a Pmax of about 30 MPa to about 275 MPa. 11. The composition of claim 1, wherein the sulfoalkyl ether cyclodextrin composition comprises a moisture content of about 5% to about 6% by weight and a compression crushing strength of about 0.5 to about 11 kP when compressed into a tablet using a Pmax of about 15 MPa to about 70 MPa. 12. The composition of claim 1, wherein 2.5 g of the sulfoalkyl ether cyclodextrin composition has an average dissolution time of about 2 mm to about 4.5 mm when placed in water. 13. The composition of claim 1, wherein the composition is a pharmaceutical composition further comprising an active agent. 14. A pharmaceutical dosage form comprising a sulfoalkyl ether cyclodextrin composition and an excipient, wherein the sulfoalkyl ether cyclodextrin composition comprises: (a) sulfoalkyl ether cyclodextrin; (b) no more than about 20% by weight moisture; (c) a bulk density of about 0.38 g/cm3 to about 0.66 g/cm3; (d) a tapped density of about 0.49 g/cm3 to about 0.75 g/cm3, wherein the tapped density of the sulfoalkyl ether cyclodextrin composition is higher than the bulk density; and (e) a gravitational-flow minimum orifice diameter of about 3 mm to about 12 mm; wherein the sulfoalkyl ether cyclodextrin composition comprises agglomerated particles, wherein the agglomerated particles are produced by a process comprising: (i) forming a fluidized bed of SALE-CD particles in a drying chamber of a fluidized bed spray dryer apparatus with an attached 3-chamber fluidization bed; (ii) recycling fine particles from the fluidized bed back into the drying chamber at a location adjacent to a liquid feed atomizer; and (iii) collecting agglomerated particles from the third chamber of the 3-chamber fluidization bed, and wherein the dosage form is selected from the group consisting of a tablet, liquid, suspension, emulsion, film, laminate, pellet, powder, bead, granule, suppository, ointment, cream, capsule, constitutable powder, dry powder inhaler, saché, troche, and lozenge. 15. The dosage form of claim 14, wherein the dosage form is a powder. 16. The dosage form of claim 14, wherein the dosage form is a tablet. 17. The dosage form of claim 16, wherein the tablet is selected from the group consisting of a controlled release tablet, an extended release tablet, a compressed tablet, a compressed rapid release tablet, and an orodispersable immediate release tablet. 18. A pharmaceutical dosage form comprising a sulfoalkyl ether cyclodextrin composition, an excipient, and an active agent, wherein the sulfoalkyl ether cyclodextrin composition comprises: (a) sulfoalkyl ether cyclodextrin; (b) no more than about 20% by weight moisture; (c) a bulk density of about 0.38 g/cm3 to about 0.66 g/cm3; (d) a tapped density of about 0.49 g/cm3 to about 0.75 g/cm3, wherein the tapped density of the sulfoalkyl ether cyclodextrin composition is higher than the bulk density; and (e) a gravitational-flow minimum orifice diameter of about 3 mm to about 12 mm; wherein the sulfoalkyl ether cyclodextrin composition comprises agglomerated particles, wherein the agglomerated particles are produced by a process comprising: (i) forming a fluidized bed of SAE-CD particles in a drying chamber of a fluidized bed spray dryer apparatus with an attached 3-chamber fluidization bed; (ii) recycling fine particles from the fluidized bed back into the drying chamber at a location adjacent to a liquid feed atomizer; and (iii) collecting agglomerated particles from the third chamber of the 3-chamber fluidization bed, and wherein the dosage form is selected from the group consisting of a tablet, liquid, suspension, emulsion, film, laminate, pellet, powder, bead, granule, suppository, ointment, cream, capsule, constitutable powder, dry powder inhaler, saché, troche, and lozenge.